Vitamin A metabolism: new perspectives on absorption, transport, and storage

1991 ◽  
Vol 71 (4) ◽  
pp. 951-990 ◽  
Author(s):  
R. Blomhoff ◽  
M. H. Green ◽  
J. B. Green ◽  
T. Berg ◽  
K. R. Norum
2019 ◽  
Vol 9 (1) ◽  
Author(s):  
Ali Saeed ◽  
Jing Yang ◽  
Janette Heegsma ◽  
Albert K. Groen ◽  
Saskia W. C. van Mil ◽  
...  

AbstractThe nuclear receptor Farnesoid X Receptor (FXR) is activated by bile acids and controls multiple metabolic processes, including bile acid, lipid, carbohydrate, amino acid and energy metabolism. Vitamin A is needed for proper metabolic and immune control and requires bile acids for efficient intestinal absorption and storage in the liver. Here, we analyzed whether FXR regulates vitamin A metabolism. Compared to control animals, FXR-null mice showed strongly reduced (>90%) hepatic levels of retinol and retinyl palmitate and a significant reduction in lecithin retinol acyltransferase (LRAT), the enzyme responsible for hepatic vitamin A storage. Hepatic reintroduction of FXR in FXR-null mice induced vitamin A storage in the liver. Hepatic vitamin A levels were normal in intestine-specific FXR-null mice. Obeticholic acid (OCA, 3 weeks) treatment rapidly reduced (>60%) hepatic retinyl palmitate levels in mice, concurrent with strongly increased retinol levels (>5-fold). Similar, but milder effects were observed in cholic acid (12 weeks)-treated mice. OCA did not change hepatic LRAT protein levels, but strongly reduced all enzymes involved in hepatic retinyl ester hydrolysis, involving mostly post-transcriptional mechanisms. In conclusion, vitamin A metabolism in the mouse liver heavily depends on the FXR and FXR-targeted therapies may be prone to cause vitamin A-related pathologies.


1955 ◽  
Vol 57 (2) ◽  
pp. 277-286 ◽  
Author(s):  
B. M. Kagan ◽  
Elizabeth Kaiser

2019 ◽  
Vol 52 ◽  
pp. 204-211 ◽  
Author(s):  
Daniel Lozano-Ojalvo ◽  
Mónica Martínez-Blanco ◽  
Leticia Pérez-Rodríguez ◽  
Elena Molina ◽  
Carmen Peláez ◽  
...  

1976 ◽  
Vol 106 (4) ◽  
pp. 569-574 ◽  
Author(s):  
J. Cecil Smith ◽  
Ellen D. Brown ◽  
E. G. McDaniel ◽  
Winnie Chan

1978 ◽  
Vol 46 (1) ◽  
pp. 19-27 ◽  
Author(s):  
Chieko Sugawara ◽  
Naoki Sugawara

Author(s):  
Manfred Kirchgessner ◽  
Franz X. Roth ◽  
Hans-Peter Roth

2020 ◽  
Author(s):  
ElHusseiny MM Abdelwahab ◽  
Judit Bovari-Biri ◽  
Gabor Smuk ◽  
Tunde Harko ◽  
Janos Fillinger ◽  
...  

Abstract Background Mutation in a tuberous sclerosis gene (TSC1 or 2) leads to continuous activation of the mammalian target of rapamycin (mTOR). mTOR activation alters cellular including vitamin A metabolism and retinoic acid receptor beta (RARβ) expression. The goal of the present study was to investigate the molecular connection between vitamin A metabolism and TSC mutation. We also aimed to investigate the effect of the FDA approved drug rapamycin and the vitamin A metabolite retinoic acid (RA) in cell lines with TSC mutation. Methods Expression and activity of vitamin A associated metabolic enzymes and RARβ were assessed in human kidney angiomyolipoma derived cell lines, primary lymphangioleiomyomatosis (LAM) tissue derived LAM cell lines as well as RARβ protein levels were tested in primary LAM lung tissue sections. TaqMan arrays, enzyme activities, qRT-PCRs, immunohistochemistry, immunofluorescent staining and western blotting were performed and analysed. The functional effects of retinoic acid (RA) and rapamycin were tested in a scratch and a BrDU assay to assess cell migration and proliferation. Results Metabolic enzyme arrays revealed a general deregulation of many enzymes involved in vitamin A metabolism including aldehyde dehydrogenases (ALDHs), alcohol dehydrogenases (ADHs) and Cytochrome P450 2E1 (CYP2E1). Furthermore, RARβ downregulation was a characteristic feature of all TSC-deficient cell lines and primary tissues. Combination of the two FDA approved drugs -RA for acute myeloid leukaemia and rapamycin for TSC mutation- normalised ALDH and ADH expression and activity, restored RARβ expression and reduced cellular proliferation and migration. Conclusion Deregulation of vitamin A metabolizing enzymes is a feature of TSC mutation. RA can normalize RARβ levels and limit cell migration, but does not have a significant effect on proliferation. Based on our data, translational studies could confirm whether combination of RA with reduced dosage of rapamycin would have more beneficial effects to higher dosage of rapamycin monotherapy meanwhile reducing adverse effects of rapamycin for patients with TSC mutation.


Sign in / Sign up

Export Citation Format

Share Document